Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolfram Hoetzenecker

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Oncoimmunology|August 8, 2020
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferationIeva Saulite, Desislava Ignatova, Yun-Tsan Chang, et al.
European Journal of Clinical Pharmacology|June 30, 2019
Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvementJennifer L Goldman, Wen-Hung Chung, Brian R Lee, et al.
European Journal of Clinical Pharmacology|March 29, 2019
Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvementJennifer L Goldman, Wen-Hung Chung, Brian R Lee, et al.
The British Journal of Dermatology|March 20, 2025
Evidence of Immunogenic Cell Death (ICD) and ICD-dependent Dendritic Cell Activation Induced by Extracorporeal Photopheresis in Patients with leukemic forms of cutaneous T cell lymphomaAngelika Lackner, Teresa Burner, Marlene Brandner, et al.
Annals of Surgical Oncology|April 22, 2017
Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal AdenocarcinomaDagmar Kollmann, Desislava Ignatova, Julia Jedamzik, et al.
Oncoimmunology|June 7, 2018
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinomaDagmar Kollmann, Desislava Ignatova, Julia Jedamzik, et al.
Nature Communications|January 25, 2024
MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoidesYun-Tsan Chang, Pacôme Prompsy, Susanne Kimeswenger, et al.
Cancer Cell|August 27, 2021
Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancerMario Mairhofer, Lea Kausche, Sabine Kaltenbrunner, et al.
EMBO Molecular Medicine|July 26, 2024
Dantrolene corrects cellular disease features of Darier disease and may be a novel treatmentMatthew Hunt, Nuoqi Wang, Naricha Pupinyo, et al.
The Journal of Allergy and Clinical Immunology|August 7, 2016
Cellular and molecular immunologic mechanisms in patients with atopic dermatitisThomas Werfel, Jean-Pierre Allam, Tilo Biedermann, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Oncoimmunology|August 8, 2020
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferationIeva Saulite, Desislava Ignatova, Yun-Tsan Chang, et al.
European Journal of Clinical Pharmacology|June 30, 2019
Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvementJennifer L Goldman, Wen-Hung Chung, Brian R Lee, et al.
European Journal of Clinical Pharmacology|March 29, 2019
Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvementJennifer L Goldman, Wen-Hung Chung, Brian R Lee, et al.
The British Journal of Dermatology|March 20, 2025
Evidence of Immunogenic Cell Death (ICD) and ICD-dependent Dendritic Cell Activation Induced by Extracorporeal Photopheresis in Patients with leukemic forms of cutaneous T cell lymphomaAngelika Lackner, Teresa Burner, Marlene Brandner, et al.
Annals of Surgical Oncology|April 22, 2017
Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal AdenocarcinomaDagmar Kollmann, Desislava Ignatova, Julia Jedamzik, et al.
Oncoimmunology|June 7, 2018
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinomaDagmar Kollmann, Desislava Ignatova, Julia Jedamzik, et al.
Nature Communications|January 25, 2024
MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoidesYun-Tsan Chang, Pacôme Prompsy, Susanne Kimeswenger, et al.
Cancer Cell|August 27, 2021
Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancerMario Mairhofer, Lea Kausche, Sabine Kaltenbrunner, et al.
EMBO Molecular Medicine|July 26, 2024
Dantrolene corrects cellular disease features of Darier disease and may be a novel treatmentMatthew Hunt, Nuoqi Wang, Naricha Pupinyo, et al.
The Journal of Allergy and Clinical Immunology|August 7, 2016
Cellular and molecular immunologic mechanisms in patients with atopic dermatitisThomas Werfel, Jean-Pierre Allam, Tilo Biedermann, et al.
Pageof 12